Skip to main content
Paul Pockros, MD, Gastroenterology, La Jolla, CA, Naval Medical Center San Diego

PaulJ.PockrosMD

Gastroenterology • La Jolla, CA

Advanced Endoscopic Interventional, Hepatology & Liver Transplantation

Physician

Join to view full profile

Dr. Pockros is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Pockros' full profile

Already have an account?

Education & Training

  • Scripps Clinic/Scripps Green Hospital
    Scripps Clinic/Scripps Green HospitalFellowship, Gastroenterology, 1982 - 1984
  • University of Southern California/LAC+USC Medical Center
    University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 1978 - 1982
  • Keck School of Medicine of the University of Southern California
    Keck School of Medicine of the University of Southern CaliforniaClass of 1978
  • University of California, San Diego
    University of California, San DiegoB.A., Biology, Magna Cum Laude, 1970 - 1974

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1979 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Top Gastroenterologist in La Jolla, CA, The Leading Physicians of The World International Association of Healthcare Professionals, 2012
  • San Diego Super Doctors The San Diego Union-Tribune, 2011
  • Best of DDW Award 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A phase 2, randomized, double-blind, placebo-controlled study of maralixibat chloride in the treatment of primary biliary cholangitis associated with itching  
    Mayo MJ, Pockros PJ, Jones D, et al, Hepatology Communications, 1/1/2019
  • Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease  
    Bernstein DE, Tran A, Martin P, Kowdley KV, Bourliere M, Sulkowski MS, Pockros PJ, et al, Kidney Int Rep, 1/1/2019
  • Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients with Hepatitis C Virus Genotype 1 or 4 Infection and Severe Renal Impairment or End-Stage Renal Di...  
    Lawitz E, Gane E, Cohen E, Vierling J, Agarwal K, Hassanein T, Mantry PS, Pockros PJ, et al, Kidney Int Rep, 1/1/2019
  • Join now to see all

Books/Book Chapters

  • Controversies in Hepatology: The Experts Analyze Both Sides 
    Chapter: Should the decompensated Hepatitis C Cirrhotic Be Treated with Antiviral Therapy. 
    Page 43 - 49Afshar P, Weissman J, Pockros PJEditors: D. Jensen.Slack, Inc.2011
  • Conn's Current Therapy 2000 
    Chapter: Cirrhosis. 
    Page 465 - 471Pockros PEditors: Rakel RE.W.B. Saunders Co., Philadelphia, PA2000
  • Schiff's Diseases of the Liver 
    Chapter: Postoperative jaundice. 
    Page 599 - 605Nyberg LM, Pockros PJEditors: Schiff ER, Sorrell ME, Maddrey WC.Lippincott-Raven Publishers, Philadelphia, PAEdition 8th,1999
  • Join now to see all

Abstracts/Posters

  • Comparative Diagnostic Performance of the PROMETHEUS (R) FIBROSpect (R) NASH Serum Test with Enhanced Liver Fibrosis (ELF TM) Test for the Identification of Advanced L...
    Jain A, Pockros P, Thomas S, et al, NASH-TAG, Park City, UT, 1/3/2019
  • Three years of Obeticholic Acid (OCA) Therapy Results in Histological Improvements in Patients with Primary Biliary Cholangitis: Further Analysis of the POISE Biopsy S...
    Bowlus CL, Pockros P, Kremer AE, et al, GASL 2019 - 35th Annual Conference of the German Association for the Study of the Liver, Berlin, Germany, 1/1/2019
  • Three years of Obeticholic Acid (OCA) Therapy Results in Histological Improvements in Patients with Primary Biliary Cholangitis: Further Analysis of the POISE Biopsy S...
    Bowlus CL, Pockros P, Kremer AE, et al, Canadian Liver Meeting, Montreal, Canada, 1/1/2019
  • Join now to see all

Lectures

  • What�s Next for PBC? 
    University of Maryland School of Medicine, Baltimore, MD - 1/1/2019
  • Roadmap to cure for chronic hepatitis B and C infections worldwide. 
    The Scripps Research Institute Graduate Studies, La Jolla, CA - 1/1/2018
  • The ABCs of PBC: An Overview of Primary Biliary Cirrhosis, Also Known as Primary Biliary Cholangitis. 
    University of New Mexico, Albuquerque, NM - 1/1/2018
  • Join now to see all

Other

  • Direct-acting antivirals for the treatment of hepatitis C virus infection. 
    Pockros PJ, UpToDate
    1/1/2016
  • Overview of the management of chronic hepatitis C virus infection. 
    Chopra S, Pockros PJ, UpToDate
    1/31/2015
  • HCV Infection: Update on Diagnosis. 
    Pockros PJ, Audio-Digest Gastroenterology
    1/1/2015
  • Join now to see all

Press Mentions

  • Pregnant Women, All Adults Should Be Tested for Hepatitis C at Least Once, Experts Say
    Pregnant Women, All Adults Should Be Tested for Hepatitis C at Least Once, Experts SayMay 28th, 2021
  • Future NASH Reimbursement Issues May Echo HCV Therapies
    Future NASH Reimbursement Issues May Echo HCV TherapiesDecember 11th, 2018
  • Conatus Pharmaceuticals to Host Expert Call on Unmet Need in HCV-SVR Patients
    Conatus Pharmaceuticals to Host Expert Call on Unmet Need in HCV-SVR PatientsFebruary 12th, 2018
  • Join now to see all

Grant Support

  • Ribavirin PLUS Infergen For Naive Chronic Hepatitis CNational Center For Research Resources2000–2002
  • Ribavirin In Chronic Hepatitis C In Comb With PEG InterfNational Center For Research Resources2000–2002
  • PEG Interferon Alpha 2A For Chronic Hepatitis CNational Center For Research Resources2000–2002
  • Oral Pantoprazole In Patients With Hepatic ImpairmentNational Center For Research Resources2000–2002
  • Interferon Alfacon 1in Chronic Hepatitis CNational Center For Research Resources2000–2002
  • VPA 985 In Liver Cirrhosis &AscitesNational Center For Research Resources1999–2002
  • Rhil 12 For Chronic Hepatitis C NON Responsive To InterferonNational Center For Research Resources1999–2002
  • Alfacon 1 Induction Compared To Standard Therapy In Hepatitis C VirusNational Center For Research Resources1999–2002
  • PEG-IFN VS Roferon A In Noncirrhotic Hepatitis CNational Center For Research Resources1998–2002
  • PEG IFN VS Roferon A For Chronic Hepatitis C With CirrhosisNational Center For Research Resources1998–2002
  • Famcyclovir For Wild Type (Hbeag+) Hepatitis BNational Center For Research Resources1997–2002
  • Screening Procedures For Identification Of Patients For ProtocolsNational Center For Research Resources1997–2000
  • OPEN Label Consensus Interferon In Hepatitis CNational Center For Research Resources1996–2000
  • COST Benefits Of Early Detection Of Rsponders Using Roferon ANational Center For Research Resources1998–1999
  • 24 And 48 Weeks Of Deescalating Roferon A In Chronic Hepatitis CNational Center For Research Resources1996–1997
  • Recombinant Methionyl Interferon Consensus In Chronic Active Hepatitis B VirusNational Center For Research Resources1996
  • R-Metifn-Con1 For Patients With Chronic Hepatitis C Virus InfectionNational Center For Research Resources1996
  • Treatment Of Malignant Ascites With Oral DiureticsNational Center For Research Resources1988–1989
  • Aldactone Therapy In Malignant Ascites/HumanNational Center For Research Resources1987

Professional Memberships

Hospital Affiliations

Dr. Paul Pockros, Dr. Paul Pockros, MD, Dr. P Pockros, Dr. Paul J. Pockros